Influence of cefodizime on the reagibility of human leukocytes

Limbert, M.; Müllner, Heidemarie; Shah, Pramod M.

doi:10.1007/bf01709952

Cited by 8 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Limbert et al [33] conducted a pilot investigation with a similar design and observed a marked increase in lymphocyte proliferation in 3 of 4 volunteers. Further ex vivo investigations in more appropriate models involving immunocompromised patients without infection confirmed that cefodizime enhances several variables of the immune system.…”

Section: Discussionmentioning

confidence: 99%

Antibiotics and Energy Delivery to the Phagocytosis-Associated Respiratory Burst in Chronic Hemodialysis Patients: A Comparison of Cefodizime and Cotrimoxazole

Vanholder

Dagrosa²,

Landschoot

et al. 1993

Nephron

View full text Add to dashboard Cite

Twenty-three stabilized chronic uremic patients with no active or recent infection were treated for 10 days with either cefodizime (5 × 2 g intravenously, n = 10) or cotrimoxazole (960 mg orally b.i.d., n = 8) in order to evaluate the effects on the depressed polymorphonuclear metabolic response to phagocytic challenge; a separate group of 5 patients received placebo. Ex vivo evaluation in whole blood of energy delivery to the phagocytosis-associated respiratory burst activity in response to latex and zymosan challenge was determined by measuring hexose-monophosphate shunt NAD(P)H-oxidase-related glycolytic activity. Cefodizime induced a statistically significant increase in the baseline-depressed glycolytic response for both latex and zymosan challenge, in contrast to cotrimoxazole and placebo. Depressed phagocytosis-related metabolic function in hemodialyzed patients was stimulated by cefodizime in recommended therapeutic doses but not by cotrimoxazole, the effect persisting for at least 2 weeks after the end of treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Antibiotics and Energy Delivery to the Phagocytosis-Associated Respiratory Burst in Chronic Hemodialysis Patients: A Comparison of Cefodizime and Cotrimoxazole

Vanholder

Dagrosa²,

Landschoot

et al. 1993

Nephron

View full text Add to dashboard Cite

show abstract

“…Cefodizime (CEF), an expanded-spectrum cephalosporin, appears to have such immunomodifying properties: in vitro, the drug has been reported to exert negative (46), neutral (32), or positive (30) effects on PMN chemotaxis; no effect (32,46) or positive effects (26,36) on phagocytosis; downregulation of tumor necrosis factor alpha (TNF-␣), interleukin-1 (IL-1), and IL-6 release by stimulated human monocytes (31,43); no effect on IL-1 release (32); and upregulation of release of IL-8 (31) and granulocyte-macrophage colonystimulating factor (38) from monocytes and bronchial epithelial cells, respectively. Ex vivo, CEF showed either neutral (12,28) or positive (12,32,59,60) effects on chemotaxis and phagocytosis by PMNs and monocytes, and it restored IL-1 and interferon production in immunocompromised patients and animals (22). In vivo, CEF enhanced phagocytosis and survival of mice infected with CEF-resistant pathogens (Candida albicans and Toxoplasma gondii) (20,22,23,27).…”

mentioning

confidence: 97%

Reduction by Cefodizime of the Pulmonary Inflammatory Response Induced by Heat-Killed Streptococcus pneumoniae in Mice

Bergeron

Ouellet

Deslauriers

et al. 1998

Antimicrob Agents Chemother

View full text Add to dashboard Cite

It has recently become apparent that overwhelming inflammatory reactions contribute to the high mortality rate associated with pneumococcal infection in immunocompetent hosts. Cefodizime (CEF) is an antibiotic that seems to be endowed with immunomodulating properties. To investigate the influence of CEF on the pulmonary inflammatory response induced by Streptococcus pneumoniae, we infected mice with repeated intranasal inoculations of 107 CFU of heat-killed fluorescein isothiocyanate-labeled bacteria, which are insensitive to the killing properties of the drug. CEF downregulated but did not abolish the strong polymorphonuclear leukocyte (PMN) recruitment induced by S. pneumoniae. PMN recruitment was not primarily mediated by leukotriene B4 in this model. The drug did not interfere with intrinsic mechanisms of phagocytosis by PMNs and alveolar macrophages. CEF totally abrogated the pneumococcus-induced tumor necrosis factor alpha (TNF-α) and interleukin-6 (IL-6) secretion in bronchoalveolar lavage fluid. The drug also prevented IL-6 release in lung homogenates and partly inhibited TNF-α, but it did not interfere with IL-1α secretion in the lungs of infected mice. The fractional and selective downregulation of inflammatory cells and cytokines by CEF suggests cell-specific and intracellular specific mechanisms of interaction of the drug. The immunomodulatory properties of CEF may help restrain excessive inflammatory reactions, thus contributing to the reported good clinical efficacy of the drug against lower respiratory tract infections.

show abstract

“…The aminothiazolylcephalosporin, cefodi zime (CDZM), is fairly unique among anti biotics in possessing immunomodulatory as well as antibacterial activity [l. 2], This ability to enhance host defense mechanisms such as phagocytosis by polymorphonuclear leuko cytes (PMN) and monocytes [3,4] and to in crease lymphocyte reactivity [5] results in su perior in vivo effectiveness when the activity of CDZM is compared with that of other cephalosporins of equal or greater in vitro an tibacterial activity. Recent studies show that the immunomodulatory activity is due to the presence of a thio-thiozyi moiety at position 3 of the cephem nucleus ( fig.…”

Section: Introductionmentioning

confidence: 99%

Comparative Study of the Effects of Cefodizime and HBW 538 in Potentiating the Production of Reactive Oxygen Species by Human Polymorphonuclear Leukocytes

et al. 1994

View full text Add to dashboard Cite

The immunomodulatory activity of cefodizime (CDZM), an aminothiazo-lylcephalosporin, was compared to that of HBW 538, a derivative of the CDZM side chain at position 3 (the mercaptothiazolyl group) in respect to the production of reactive oxygen species (ROS) by human whole blood and polymorphonuclear leukocytes (PMN) in vitro. Ten-fold diluted whole blood and PMN from healthy individuals were incubated with CDZM or HBW 538 alone at the concentrations of 1,10, or 100 μg/ml, or CDZM or HBW 538 at 100 μg/ml in combination with tumor necrosis factor-α (TNF-α) at 100 U/ml or lipopolysaccharide (LPS) at 1 μg/ml. The production of ROS was measured by a chemiluminescence (CL) assay in which luminol was added to a mixture and after which the PMN or whole blood were stimulated with nonopsonized zymosan or phorbol myristate acetate. The following results were obtained: (1) The CL responses of whole blood and PMN were slightly but not significantly enhanced by CDZM at 100 μg/ml, whereas both CL responses were significantly enhanced by exposure to HBW 538 at 10 and 100 μg/ml. (2) The enhanced PMN CL response which followed priming with TNF-α or LPS was not augmented by CDZM but was significantly augmented by HBW 538. These results indicate that the ability of the HBW 538 molecule to enhance the production of ROS by stimulated PMN and to act agonistically with TNF-α or LPS is abrogated when HBW 538 is part of the CDZM molecule. These findings have important clinical implications as they indicate that treatment with CDZM in patients with severe gram-negative septicemia would not increase tissue injury by enhancing the already excessive release of ROS by stimulated and LPS- or TNF-α-primed PMN.

show abstract

Influence of cefodizime on the reagibility of human leukocytes

Cited by 8 publications

References 8 publications

Antibiotics and Energy Delivery to the Phagocytosis-Associated Respiratory Burst in Chronic Hemodialysis Patients: A Comparison of Cefodizime and Cotrimoxazole

Antibiotics and Energy Delivery to the Phagocytosis-Associated Respiratory Burst in Chronic Hemodialysis Patients: A Comparison of Cefodizime and Cotrimoxazole

Reduction by Cefodizime of the Pulmonary Inflammatory Response Induced by Heat-Killed Streptococcus pneumoniae in Mice

Comparative Study of the Effects of Cefodizime and HBW 538 in Potentiating the Production of Reactive Oxygen Species by Human Polymorphonuclear Leukocytes

Contact Info

Product

Resources

About